英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

padded    音标拼音: [p'ædəd] [p'ædɪd]
v. 填补
vbl. 填补

填补填补

padded
adj 1: softened by the addition of cushions or padding [synonym:
{cushioned}, {cushiony}, {padded}]

Pad \Pad\, v. t. [imp. & p. p. {Padded}; p. pr. & vb. n.
{Padding}.]
1. To stuff; to furnish with a pad or padding.
[1913 Webster]

2. (Calico Printing) To imbue uniformly with a mordant; as,
to pad cloth. --Ure.
[1913 Webster]


padded \padded\ adj.
Same as {cushioned}, 1.

Syn: cushioned, cushiony.
[WordNet 1.5]

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Broader Adoption of SGLT2 Inhibitors in Clinical Practice
    Over the past decade, the indications for sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney and cardiovascular risk reduction have expanded, driven by clinical trial evidence demonstrating their efficacy among individuals with chronic kidney disease (CKD), heart failure, diabetes, and
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • NEXLIZET® NEXLETOL® Other Outcomes Trial Information
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • Therapeutic Value of SGLT2 Inhibitors in the Management of . . .
    SGLT2 inhibitors have transformed the treatment of cardiovascular disease, providing substantial therapeutic promise for a wide range of patients They are anticipated to become more and more important in the prevention and management of cardiovascular disease
  • Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores . . .
    Background: Cardiovascular disease (CVD) is a leading cause of mortality in Type 2 diabetes mellitus (T2DM) Sodium-glucose co-transporter 2 (SGLT2) inhibitors are known to provide cardioprotective effects, but their influence on validated cardiovascular risk models remains underexplored This study assessed the impact of SGLT2 inhibitors on cardiovascular risk scores, metabolic parameters
  • FinancialContent - Esperion Showcases New Data from CLEAR . . .
    “These new analyses from CLEAR Outcomes further strengthen the evidence base supporting NEXLETOL as a proven therapy for cardiovascular risk reduction - especially for patients who cannot tolerate statin therapy,” said Sheldon Koenig, President and Chief Executive Officer of Esperion
  • Esperion Showcases New Data from CLEAR Outcomes Highlighting . . .
    In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture
  • FDA approves broad new labels for Nexletol ( bempedoic acid . . .
    Esperion announced that the FDA has approved broad new label expansions for Nexletol (bempedoic acid) Tablets and Nexlizet (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients





中文字典-英文字典  2005-2009